IAVI and the Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, announced that the Bill & Melinda Gates Foundation has awarded IAVI US$55 million to conduct a Phase IIb trial assessing the safety and efficacy of the TB vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults. It is anticipated that the trial will begin enrolling participants in mid-2024.
Read the full press release here.
For more TB news, check out the latest edition of the TB Online Weekly Newsletter (#39, 21 December 2023) with the latest TB advocacy and research updates.
Source : IAVI
Related HIV and Co-Infections News
-
The Lancet Global Health: Untangling the complex relationship between HIV-exposure and TB in children: A narrative review
-
Research Centre Borstel: Long-term cure rates for multidrug-resistant TB much better than expected
-
Liverpool School of Tropical Medicine: New pooled testing toolkit to help expand TB diagnosis to ‘missed millions’
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.